Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Mayne Pharma Group ( (AU:MYX) ) is now available.
Mayne Pharma Group has notified the market that 241,192 performance rights (ASX code: MYXAN) have lapsed after the conditions attached to these conditional rights were not met or became incapable of being satisfied as of 16 December 2025. The cessation of these securities effectively reduces the company’s potential future share dilution under its incentive arrangements and may signal that certain performance or vesting hurdles tied to these rights were not achieved, which could be relevant for investors tracking executive or employee equity incentives and capital structure dynamics.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australian-listed pharmaceutical company (ASX: MYX) that develops and manufactures branded and generic medicines, with a focus on specialty and complex formulations for global markets.
Average Trading Volume: 563,933
Technical Sentiment Signal: Sell
Current Market Cap: A$253.5M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.